Sogroya

News

NHS cleared to use Novo Nordisk's long-acting growth hormone

Novo Nordisk's long-acting injectable Sogroya has been backed for NHS use in young people with growth hormone deficiency.

News

Novo Nordisk builds case for Norditropin successor

Novo Nordisk's long-acting growth hormone Sogroya works as well as Norditropin in a trio of paediatric growth disorders, with far fewer injections.

News

NHS "isn't delivering equitable care for rare diseases"

A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks